Noninvasive PET-MR Imaging of Histone Deacetylase Activity in the Heart Using 11C-Martinostat in Healthy Adults, Diabetes Patients, and Aortic Stenosis Patients

What this Trial Is About

Researchers are evaluating 11C-Martinostat, a special imaging agent that targets histone deacetylases HDACs, enzymes involved in heart conditions such as heart failure, left ventricular hypertrophy, and myocardial fibrosis. This study aims to understand HDAC activity in the hearts of healthy people and patients with severe aortic stenosis or diabetes. The goal is to help guide future heart failure treatments and improve prognosis using noninvasive imaging techniques. Participants include healthy volunteers, patients with diabetes, and patients with aortic stenosis. All receive an intravenous injection of 11C-Martinostat followed by simultaneous PET-MRI scans. Patients with aortic stenosis will have scans before and after transcatheter valve replacement. This helps assess HDAC expression and the impact of treatment. During the study, participants will undergo PET-MR imaging to measure 11C-Martinostat binding in the heart between 10 and 60 minutes after injection. Researchers will collect data from imaging scans to evaluate HDAC activity. The study includes adults aged 18 to 85 years without contraindications to MRI. Participation involves providing informed consent and completing imaging procedures under medical supervision.

Imaging Histone Deacetylase in the Heart